CN113336795A - 胆碱磷酸单体及其聚合物以及应用 - Google Patents
胆碱磷酸单体及其聚合物以及应用 Download PDFInfo
- Publication number
- CN113336795A CN113336795A CN202110614144.6A CN202110614144A CN113336795A CN 113336795 A CN113336795 A CN 113336795A CN 202110614144 A CN202110614144 A CN 202110614144A CN 113336795 A CN113336795 A CN 113336795A
- Authority
- CN
- China
- Prior art keywords
- copolymer
- phosphocholine
- monomer
- group
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000178 monomer Substances 0.000 title claims abstract description 34
- 229920000642 polymer Polymers 0.000 title abstract description 15
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 title description 12
- 229960001231 choline Drugs 0.000 title description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 title description 4
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims abstract description 36
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 20
- 229950004354 phosphorylcholine Drugs 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 4
- YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000000017 hydrogel Substances 0.000 claims description 31
- -1 polyoxymethylene Polymers 0.000 claims description 28
- 229920001577 copolymer Polymers 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000000524 functional group Chemical group 0.000 claims description 8
- 229920001519 homopolymer Polymers 0.000 claims description 8
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 7
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 239000003519 biomedical and dental material Substances 0.000 claims description 6
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 239000003999 initiator Substances 0.000 claims description 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 230000003385 bacteriostatic effect Effects 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000000416 hydrocolloid Substances 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- 239000004593 Epoxy Substances 0.000 claims description 3
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 2
- 239000004709 Chlorinated polyethylene Substances 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 239000004642 Polyimide Substances 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 claims description 2
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 238000010382 chemical cross-linking Methods 0.000 claims description 2
- 239000000084 colloidal system Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 2
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 claims description 2
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 239000000622 polydioxanone Substances 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920002620 polyvinyl fluoride Polymers 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 229930040373 Paraformaldehyde Natural products 0.000 claims 1
- 229920000098 polyolefin Polymers 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000000499 gel Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000011521 glass Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 238000004679 31P NMR spectroscopy Methods 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 239000002086 nanomaterial Substances 0.000 description 6
- 239000011664 nicotinic acid Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 206010061307 Neck deformity Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003592 biomimetic effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003373 anti-fouling effect Effects 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000006392 deoxygenation reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000002407 tissue scaffold Substances 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- SHMWBGKFKOTOOI-UHFFFAOYSA-N 3-azidopropyl 2-bromo-2-methylpropanoate Chemical compound CC(C)(Br)C(=O)OCCCN=[N+]=[N-] SHMWBGKFKOTOOI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- WNTBJYCCQGOFKH-UHFFFAOYSA-N acetylene butan-1-ol Chemical compound C#C.C(CCC)O WNTBJYCCQGOFKH-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- WDHYRUBXLGOLKR-UHFFFAOYSA-N phosphoric acid;prop-2-enoic acid Chemical compound OC(=O)C=C.OP(O)(O)=O WDHYRUBXLGOLKR-UHFFFAOYSA-N 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001510 poly[2-(diisopropylamino)ethyl methacrylate] polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 238000003380 quartz crystal microbalance Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F130/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
- C08F130/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing phosphorus
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F287/00—Macromolecular compounds obtained by polymerising monomers on to block polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F30/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
- C08F30/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing phosphorus
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F38/00—Homopolymers and copolymers of compounds having one or more carbon-to-carbon triple bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/01—Atom Transfer Radical Polymerization [ATRP] or reverse ATRP
Abstract
本发明提供了一种胆碱磷酸单体及其聚合物以及应用,具体提供了一种胆碱磷酸单体,具有式Ⅰ所示结构。本发明提供的胆碱磷酸单体及聚合物用于生物医用材料领域,可以显著提高材料的稳定性、生物相容性、抗污性、长效抑菌性,并且提高了药物分子的利用率,在多个领域拥有广泛的应用前景。
Description
技术领域
本发明涉及生物医用材料技术领域,尤其涉及一种胆碱磷酸单体及其聚合物以及应用。
背景技术
随着社会不断的发展,生物医用材料不断的涌现。近年来纳米材料得到了广泛的关注。纳米材料根据其拥有独特的性质,可以改善药物在生物体内的分布,从而增强疗效。其中纳米颗粒的稳定性和靶向性对于其在生物体中的应用是两个最重要的问题。需要通过设计和改性纳米颗粒使其稳定并具有功能性,从而解决这两个问题。聚乙二醇(PEG)是近年来十分成功的一个生物医用材料,通过将聚乙二醇与纳米材料表面缀合,利用PEG的非特异性抗蛋白吸附特性(抗污染特性),从而达到保护纳米颗粒的作用。然而聚乙二醇的易氧化特性限制了其对于长期使用纳米材料稳定性的应用的效用,并且聚乙二醇本身具有疏水性的特性,这种特性会大大降低纳米材料长期使用的稳定性和抗污性,需要添加其他材料来折中疏水性。所以对于要求生物稳定性和抗污性高的纳米材料,基于PEG的应用显然是不够的。
水凝胶材料也是一类被广泛关注的生物医用材料,由于其高度仿生细胞外基质(ECM)结构,提供生物模拟性的机械强度,水凝胶常常被用作隐形眼镜、抗菌敷贴、体内植入物等。特别令人感兴趣的是PEG水凝胶和聚甲基丙烯酸羟乙酯(PHEMA)水凝胶,这两种材料除了水凝胶的一般特性以外,它们还拥有低污染、生物惰性和万用的特性。PEG与PHEMA水凝胶被广泛应用于隐形眼镜,药物递送载体,组织支架。然而这两种水凝胶的水合特性,抗污特性和稳定性依然难以满足长期使用的生物材料的要求,所以研发一种新型的具有高抗污性和长期稳定性材料具有重大意义。
近年来两性离子化合物(如磷脂酰胆碱甲基丙烯酸酯,羧基甜菜碱丙烯酸酯等)显示出巨大的应用前景。两性离子化合物普遍被认为是超级抗污性的,这是因为其两种相反离子所产生的高度水合作用,导致异物接触材料表面除去水合层需要高能量,从而减少异物的吸附,并且两性离子基团不易被氧化,使两性离子材料可以长期稳定的使用。磷脂酰胆碱甲基丙烯酸酯是一类模仿细胞膜头基磷脂酰胆碱的一类两性离子单体,被石原一彦发明并在多个领域中应用。由于其高度仿生细胞膜,其具有高度的仿生性,可以用作纳米载药系统、隐形眼镜、抗菌敷贴、蛋白缀合物、组织支架等多种材料,与人体具有良好的相容性。然而磷脂酰胆碱类基团单体合成困难,核心技术掌握在日本株式会社资生堂等公司手中,在中国难以实现规模化生产。此外磷脂酰胆碱类基团由于磷酸基团与高分子链相连,胆碱基团游离在外,所以难以对其进行功能化修饰,减少了它的功能性。所以一种具有高度仿生,合成简单,可功能化特性的两性离子化合物具有广泛的应用前景。
因此,构建一种具有高度仿生性、抗污性、稳定性、可修饰性的生物医用材料具有重大意义。
发明内容
有鉴于此,本发明要解决的技术问题在于提供一种胆碱磷酸单体及其聚合物以及应用,可以显著提高材料的稳定性、生物相容性、抗污性。
为达到上述目的,本发明提供了一种胆碱磷酸单体,具有式Ⅰ所示结构:
其中,R1、R2独立的选自取代或非取代烷基;
R3为磷酸基团进一步修饰的功能化基团;
R4为H或者CH3;
L1是将阳离子中心[N+(R1)(R2)]与单体双键CH2=CH共价偶联的连接子。
胆碱磷酸基团是一类新型特殊的两性离子基团,该设计源自于将细胞膜骨架分子亲水头部基团,磷脂酰胆碱电荷的“取向异位”,在保留了磷脂酰胆碱两性离子结构的同时还赋予了其新的功能,如磷酸基团可功能化特性。基于以上特性,两性离子胆碱磷酸材料可以构建出高度仿生性、抗污性、稳定性、可修饰性的生物医用材料。
本发明优选的,所述R1、R2独立的选自取代或非取代的C1-C4的烷基;更优选为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基;进一步优选为甲基。
所述R3为磷酸基团进一步修饰的功能化基团,进而实现分子的功能化。
本发明优选的,所述R3选自取代或非取代的C1-C8的烷基、C3-C8的烯基、C3-C8的炔基、C3-C8的环氧基、C3-C8的叠氮基、C3-C8的氨基、多元醇类物质中除去任一羟基后剩余的残基、选择保护基团。
更优选的,所述R3选自取代或非取代的甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、烯丙基、烯丁基、炔丙基、炔丁基。
所述选择保护基团优选为苄氧羰基(Cbz)、叔丁氧羰基(Boc)、笏甲氧羰基(Fmoc)、烯丙氧羰基(Alloc)、三甲基硅乙氧羰基(Teoc)、甲氧羰基、乙氧羰基、邻苯二甲酰基(Pht)、对甲苯磺酰基(Tos)、三氟乙酰基(Tfa)、三苯甲基(Trt)、二甲氧基苄基(Dmb)、对甲氧基苄基(PMB)、苄基(Bn)等本领域技术人员熟知的保护性基团。
上述选择保护基团用于对一些不稳定基团,如氨基等进行保护,经保护的基团在适当时候需要脱保护,本发明对脱保护的策略并没有详细的限定,只要是化学合成中常用的或针对某一种保护基团特有的脱保护策略即可。
本发明优选的,所述L1选自-C(=O)O-(CH2)n-、-C(=O)NH-(CH2)n-、-C(=O)O-(CH2CH2O)n-1-CH2CH2-或-C(=O)NH-(CH2CH2O)n-1-CH2CH2-,其中n是1-20的整数。
所述n更优选为1~10的整数,进一步优选为1~5的整数,具体可以选自1、2、3、4或5,或以上述任意值为上限或下限的区间。
更优选的,所述L1选自-C(=O)O-(CH2)2-。
本发明提供了一种胆碱磷酸均聚物或共聚合物,具有式Ⅱ所示结构:
其中,R1、R2独立的选自取代或非取代烷基;
R3为磷酸基团进一步修饰的功能化基团;
R4为H或者CH3;
L1是将阳离子中心[N+(R1)(R2)]与单体双键CH2=CH共价偶联的连接子;
m为2-10,000的整数;
X1、X2独立的选自亲水性聚合物或疏水性聚合物;
其中,X1、X2同时存在或任选的一个存在。
所述R1、R2、R3、R4、L1的优选范围同上,在此不再赘述。
所述m优选为2~5000的整数;更优选为2~1000的整数;进一步优选为2~500的整数。
本发明优选的,所述X1、X2为嵌段聚合物。所述X1、X2的平均分子量优选为约1,000至约200,000。所述分子量为数均分子量。
本发明优选的,所述X1、X2独立的选自聚丙烯酸,聚丙烯腈,聚己酸内酯,聚乙交酯,聚乳酸,聚酰胺,聚氨酯,聚乙烯,氯化聚乙烯,聚氟乙烯,聚乙烯醇,聚甲醛,聚丙烯,氯化聚丙烯,聚苯乙烯,聚四氟乙烯,聚对苯二甲酸乙二(醇)酯,聚酰亚胺,聚甲基丙烯酰亚胺,聚甲基丙烯酸甲酯,聚硅氧烷,聚-2-(二异丙基氨基)丙烯酸乙酯,聚-3-羟基丁酸酯,聚二氧杂环己酮,聚三亚甲基碳酸酯,聚羧甲基纤维素,聚丙酸纤维素,乙交酯己内酯共聚物,丙烯腈-丁二烯-苯乙烯共聚物,丙烯腈-苯乙烯共聚物,丙烯腈-甲基丙烯酸酯共聚物,氯乙烯-甲基丙烯酸甲酯共聚物,乙烯-丙烯共聚物,全氟(乙烯-丙烯)共聚物,氯乙烯-丙烯酸甲酯共聚物,乙交酯三亚甲基碳酸脂共聚物和二氧杂环己酮-三亚甲基碳酸酯-乙交酯共聚物。
本发明中,X1、X2同时存在或任选的一个存在。当X1、X2同时存在时,所述聚合物为同时含X1和X2嵌段的三嵌段聚合物。当X1、X2任选的一个存在时,所述聚合物为含X1或X2嵌段的二嵌段聚合物。
本发明提供了一种胆碱磷酸酯水凝胶,由胆碱磷酸单体,在交联剂存在的条件下,进行化学交联制备得到;
所述胆碱磷酸单体为上述胆碱磷酸单体中的一种或多种,或上述胆碱磷酸均聚物或共聚合物中的一种或多种。
本发明优选的,所述交联剂选自N,N-亚甲基双丙烯酰胺。
本发明优选的,所述化学交联的条件选自引发剂、紫外光照、加热、辐射中的一种或几种。
本发明对所述引发剂并无特殊限定,可以为本领域技术人员熟知的适用引发剂。
所述紫外光照的波长优选为小于400纳米,光照时间优选为0.5-10小时。
所述加热的时间优选为0.5-10小时,温度优选为30-100℃。
本发明提供了上述胆碱磷酸单体,或上述胆碱磷酸均聚物或共聚合物,或上述胆碱磷酸酯水凝胶,作为生物医用材料的应用。
本发明优选的,所述生物医用材料包括治疗成分的载体、医疗器械、医用敷料、医用敷贴中的一种或多种。
本发明优选的,所述治疗成分包括药物、基因、激素、疫苗等中的一种或多种。
本发明优选的,所述医疗器械包括稀释剂、抗生物污染、抑菌、植入器械表面抗污涂层等。
本发明优选的,所述医用敷料包括水胶体抗菌敷料、水胶体清洁抗菌促愈合敷料等中的一种或多种。
本发明优选的,所述医用敷贴包括医用一次性抗菌敷贴,粘贴型抗菌敷贴,透明抗菌敷贴,伤口胶体敷贴等。
本发明提供的上述胆碱磷酸单体,或上述胆碱磷酸均聚物或共聚合物,也可以作为与其他任何材料共同组合得到的功能改性材料。
与现有技术相比,本发明提供了一种胆碱磷酸单体,具有式Ⅰ所示结构。
本发明提供的胆碱磷酸单体结构中,胆碱磷酸部分是高度仿生细胞膜骨架分子的亲水头基磷脂酰胆碱基团,通过对磷脂酰胆碱基团的“取向异位”构建了具有功能化的胆碱磷酸基团,在保留细胞膜头基的同时赋予了其可修饰性的特性。所以胆碱磷酸分子在具有两性离子性能的同时,还具有一些其他特性,如易成膜性,可高效包载药物,与生物分子有优异的缀合相容性,并且具备抗蛋白吸附的同时促进细胞内化等特性。除此之外,本发明提供的上述单体和聚合物的每个重复单元都可以进行功能化修饰,这取决于磷酸基团上的R3基团。R3基团可根据需求合成出具有不同结构的官能团,而这些丰富的可修饰的官能团,可赋予胆碱磷酸单元优异的后修饰性,制备功能多样、用途各异的生物制剂,从而为疾病的诊断和治疗提供更多优异的选择。本发明提供上述的胆碱磷酸结构的聚合物具有高度仿生性、抗污性、长效抑菌性、稳定性、可修饰性等性能,可用于制备多种生物医用材料。
附图说明
图1为丙烯酰氧乙基胆碱磷酸乙酯的氢谱,磷谱的NMR图;
图2为实施例2制备的丙烯酰氧乙基胆碱磷酸丁炔酯的氢谱,磷谱的NMR图;
图3为实施例3制备水凝胶的透射电镜照片;
图4为实施例3制备水凝胶的力学性能测试图;
图5为实施例3制备水凝胶的生物安全性能——溶血率;
图6为实施例3制备水凝胶的生物安全性能——细胞存活率;
图7为实施例3中各种水凝胶的蛋白吸附量结果;
图8为实施例3中PACP高分子材料的抑菌性能测试。
具体实施方式
为了进一步说明本发明,下面结合实施例对本发明提供的胆碱磷酸单体及其聚合物以及应用进行详细描述。
实施例1部分丙烯酸胆碱磷酸酯单体的制备
将三乙胺(51g,0.51mol)、无水甲醇(16g,0.5mol)加入到装有300mL无水四氢呋喃的支口烧瓶中,氮气保护下磁力搅拌,在冰水浴中冷却30分钟后,从恒压滴液漏斗中滴加2-氯-2-氧-二氧磷杂环戊烷(71g,0.5mol),滴加过程中反应体系产生大量白色沉淀,1小时内滴加完毕,保持冰水浴反应2小时后缓慢升至室温,继续反应2小时,过滤,用无水四氢呋喃洗涤滤饼两次,滤液合并收集,减压除去溶剂后得到粗品,粗品经短颈蒸馏,得纯品2-氧甲基-2-氧-二氧磷杂环戊烷43.5g,产率63%。产物结构如下:
1H-NMR(500MHz,CDCl3):4.44-4.35(m,-OCH2CH2O-),4.15(s,-OCH3);31P-NMR(500MHz,CDCl3):δ(ppm)17.60(s).
将2-氧甲基-2-氧-二氧磷杂环戊烷(4.21g,30mmol),2-(二甲氨基)丙烯酸乙酯(5.2g,33mmol)和100mg阻聚剂BHT加入到装有50mL无水乙腈的100毫升烧瓶中,加热到70℃反应56小时,反应结束后将溶液在500mL的四氢呋喃溶液中沉淀三次,最后除去四氢呋喃得到产物丙烯酰氧乙基胆碱磷酸乙酯5.6g,产率63%,产物结构如下:
1H-NMR(500MHz,D2O):6.43and 6.21(d and m,-OCCH=CH2),6.03(d,-OCCH=CH2),4.64(t,-CH2O-CO-),4.29(t,-CH2OP),3.86(m,-CH2N(CH3)2-CH2-),3.74(s,P-OCH3),3.25(s,-N-(CH3)2);31P-NMR(500MHz,D2O):δ(ppm)0.05(s).
将三乙胺(51g,0.51mol)、无水乙醇(22g,0.5mol)加入到装有300mL无水四氢呋喃的支口烧瓶中,氮气保护下磁力搅拌,在冰水浴中冷却30分钟后,从恒压滴液漏斗中滴加2-氯-2-氧-二氧磷杂环戊烷(71g,0.5mol),滴加过程中反应体系产生大量白色沉淀,1小时内滴加完毕,保持冰水浴反应2小时后缓慢升至室温,继续反应2小时,过滤,无水四氢呋喃洗涤滤饼两次,滤液合并收集,减压除去溶剂后得到粗品,粗品经短颈蒸馏,得纯品2-氧乙基-2-氧-二氧磷杂环戊烷49.4g,产率65%。产物结构如下:
1H-NMR(500MHz,CDCl3):4.44-4.35(m,-OCH2CH2O-),4.15(m,-OCH2CH3),1.41(t,-OCH2CH3);31P-NMR(500MHz,CDCl3):δ(ppm)17.60(s).
将2-氧乙基-2-氧-二氧磷杂环戊烷(4.72g,30mmol),2-(二甲氨基)丙烯酸乙酯(5.2g,33mmol)和100mg阻聚剂BHT加入到装有50mL无水乙腈的100毫升烧瓶中,加热到70℃反应56小时,反应结束后将溶液在500mL的四氢呋喃溶液中沉淀三次,最后除去四氢呋喃得到产物丙烯酰氧乙基胆碱磷酸乙酯5.6g,产率63%,产物结构如下:
1H-NMR(500MHz,D2O):6.43and 6.21(d and m,-OCCH=CH2),6.03(d,-OCCH=CH2),4.64(t,-CH2O-CO-),4.29(t,-CH2OP),3.86(m,-CH2N(CH3)2-CH2-),3.74(d,P-OCH2-CH2-),3.25(s,-N-(CH3)2),1.25(t,P-OCH2-CH3);31P-NMR(500MHz,D2O):δ(ppm)0.06(s).
其氢谱,磷谱的NMR图如图1所示。
实施例2
可功能化丙烯酸胆碱磷酸酯单体的制备
将三乙胺(51g,0.51mol)、无水炔丁醇(35g,0.5mol)加入到装有150mL无水四氢呋喃的支口烧瓶中,氮气保护下磁力搅拌,在冰水浴中冷却30分钟后,从恒压滴液漏斗中滴加2-氯-2-氧-二氧磷杂环戊烷(71g,0.5mol),滴加过程中反应体系产生大量白色沉淀,1小时内滴加完毕,保持冰水浴反应2小时后缓慢升至室温,继续反应2小时,过滤,用无水四氢呋喃洗涤滤饼两次,滤液合并收集,减压除去溶剂后得到粗品,粗品经短颈蒸馏,得纯品2-氧丁炔基-2-氧-二氧磷杂环戊烷(COP)44g,产率50%。产物结构如下:
1H-NMR(500MHz,CDCl3):4.47(m,-OCH2CH2O-),4.26(m,-OCH2CH2C≡CH),2.45(m,-OCH2CH2C≡CH),31P-NMR(500MHz,CDCl3):δ(ppm)17.35(s).
将COP(5.34g,30mmol),2-(二甲氨基)甲基丙烯酸乙酯(5.2g,33mmol)和100毫克阻聚剂BHT加入到装有50mL无水乙腈的100毫升烧瓶中,氮气保护下加热到70℃反应56小时,反应结束后将溶液在500mL的四氢呋喃溶液中沉析三次,最后分离除去四氢呋喃得到5.1克产物MCP,产率53%,产物结构如下:
1H-NMR(500MHz,D2O):6.43and 6.24(d and m,-OCCH=CH2),6.03(d,-OCCH=CH2),4.65(t,-CH2O-CO-),4.34(t,-CH2OP),3.95-3.86(m,-CH2N(CH3)2-CH2-),3.77(d,P-OCH2-CH2-),3.26(s,-N-(CH3)2),2.65(s,P-OCH2-CH2-C≡CH),2.55(m,P-OCH2-CH2-C≡CH);31P-NMR(500MHz,D2O):δ(ppm)-0.65(s).
其氢谱,磷谱的NMR图如图2所示。
实施例3丙烯酸胆碱磷酸酯共聚物及其水凝胶的制备以及性能表征
将引发剂2-溴-2-甲基丙酸3-叠氮丙基酯(2.5mg,1mmol)、2,2-联吡啶(0.312g,2mmol)、丙烯酰氧乙基胆碱磷酸乙酯(7.03g,25mmol)加入到装有30mL无水甲醇的Schlenk瓶中,在氮气环境下进行3次冷冻-解冻-脱氧气,在氮气保护下加入溴化亚铜(143mg,1mmol)。反应在室温下进行,24小时后将混合物暴露在空气中终止反应,后将混合物在去离子水中透析(透析袋MWCO 2000),24小时后将样品冷冻干燥,得产物PACP25。产物结构如下:
1H-NMR(500MHz,D2O):4.64(t,-CH2O-CO-),4.29(t,-CH2OP),3.86(m,-CH2N(CH3)2-CH2-),3.72(d,P-OCH2-CH2-),3.68(s,P-OCH3),3.26(s,-N-(CH3)2),2.56(t,-OC-CH-CH2-),1.75(s,-CH2-C-);31P-NMR(500MHz,D2O):δ(ppm)0.05(s).
将PACP25-Br(3.81g,0.5mmol)、2,2-联吡啶(0.312g,2mmol)、2-(二异丙基氨基)丙烯酸乙酯(DPA,13.2g,62mmol)加入到装有40mL无水甲醇的Schlenk瓶中,在氮气环境下进行3次冷冻-解冻-脱氧气,之后迅速加入溴化亚铜(143mg,1mmol)。反应在室温下进行,48小时后将混合物暴露在空气中终止反应,后将混合物在去离子水中透析(透析袋MWCO2000),24小时后将样品冷冻干燥,得产物PACP25-b-PDPA120。产物结构如下:
1H-NMR(500MHz,D2O):4.64(t,-CH2O-CO-),4.49(t,-N-CH2-CH2O-CO-),4.29(t,-CH2OP),3.86(m,-CH2N(CH3)2-CH2-),3.78(m,-CH-N(CH2)-CH-),3.72(d,P-OCH2-CH2-),3.68(s,P-OCH3),3.51(t,-N-CH2-CH2O-CO-),3.26(s,-N-(CH3)2),2.52(t,-OC-CH-CH2-),1.75(s,-CH2-C-),1.38(d,CH3-CH-);31P-NMR(500MHz,D2O):δ(ppm)0.05(s).
在1M NaCl溶液中,制备嵌段共聚物PACP25-b-PDPA120浓度为5%以及丙烯酸(或甲基丙烯酸)单体浓度为50wt%的混合溶液,并加入0.1%-10%交联剂N,N-亚甲基双丙烯酰胺(MBA,摩尔百分比)。上述混合溶液在4℃超声条件下,依次加入40%过硫酸钾溶液和15%焦亚硫酸钠,10分钟后将上述混合液注入由1mm聚四氟乙烯(PTFE)间隔开的两块玻璃板之间,升温至60℃,并在此条件下聚合5小时。然后将上述聚合完成的凝胶从玻璃板上取出并将其浸没在大量PBS溶液中,PBS溶液每天更换,持续5天以除去未反应单体和盐。最后使用活组织检查冲压机将水凝胶剪切成待测试的形状和尺寸。
制备的水凝胶的透射电镜照片如图3所示。
1、力学性能测试:
采用垂直压缩实验(GB/T 1041-1992)评价材料的力学性能。在20℃条件下,将面积20×20mm2及厚度为10mm的块状样品加载到测试夹具上,调节机架到合适位置,以2mm/min的压缩速率进行压缩实验。
测试图如图4所示,其中从左到右依次为测试横向拉伸、纵向拉伸、剥离强度的测试图。
测试结果如表1所示:
表1力学性能测试结果
测试材料 | 横向拉伸/KPa | 纵向拉伸/KPa | 剥离强度/KPa |
金属 | 70 | 68 | 50 |
玻璃 | 38 | 45 | 38 |
硅橡胶 | 20 | 20 | 23 |
皮肤 | 16 | 22 | 20/剥离无残留 |
2、孔隙率和溶胀比测试
用乙醇浸没法测试样品的孔隙率,首先测量乙醇初始体积和干凝胶质量,然后将干凝胶浸入无水乙醇中饱和后称重饱和凝胶质粒,利用公式-1计算水凝胶的孔隙率。PACP凝胶孔隙率最高可以达到50%。
W1:原始乙醇的质量;
W2:乙醇和浸没样品的总质量;
W3:移除样品后乙醇的质量。
凝胶的溶胀比:
凝胶冻干后称重干态凝胶重量,在37℃溶液中将凝胶饱和24小时然后,称重饱和凝胶的重量,利用公式-2计算溶胀比。PACP凝胶的溶胀比分别为:3.8g/g(去离子水),3.4g/g(PBS),3.2g/g(生理盐水)。
Ws:凝胶饱和后的质量;
Wd:凝胶干态的质量。
3、吸水性能测试:
用质量法测定PACP凝胶材料的吸水性能。
称取一定质量PACP样品置于20℃去离子水中,取出不同时间间隔样品(如:30s、60s、120s、180s、240s、300s、360s、420s、480s、540s及600s),在不锈钢滤网上30s去除表面水,称量质量,利用公式-3计算样品吸水量随时间的变化。该凝胶体系的饱和吸附量高达20.6g/g。
W2:PACP凝胶原始样品的干态质量;
Wt:样品在20℃去离子水中浸泡t时时刻的质量。
4、透气性能测试:
测量方法如下:首先,在开口直径为15mm的玻璃容器中,加入去离子水(10mL);然后,将厚度为3mm凝胶覆盖在玻璃容器瓶口之上,测量玻璃瓶的整体质量;最后,将凝胶封口的玻璃容器放在37℃烘箱中持续24h后,测量该玻璃容器的最终质量,利用公式-4计算水蒸气透过率。该凝胶的水蒸气透过率最高可以达到1324g/m2/d。
A:玻璃容器瓶口面积;
Wi:玻璃容器初始质量;
Wf:玻璃容器最终质量;
t:时间。
5、溶血率测试:
首先,配制在412nm处的吸光度为0.6的红细胞标准溶液,分别切取凝胶0.01g于样品管中,加入1.5mL红细胞标准溶液,在37℃条件下培养1小时,离心,取上层清液并稀释十倍,然后测试溶液在412nm处的吸光度。其中,阳性对照组:100%溶血溶液;阴性对照组:红细胞标准溶液。利用公式-5计算溶血率。该凝胶的溶血率仅为11%,具有优异的生物安全性能。
溶血率测试结果如图5所示。
6、细胞毒性测试:
参照ISO 10993-5标准,利用MTT法,PBS溶液和Nano-Ag作为对照组,将Hela细胞以每孔9,000个细胞的密度转移到96孔平底平板上,并孵育24小时。然后,除去培养基,并分别加入新鲜的无血清的RPMI-1640(凝胶浓度0.1g/mL)。孵育24小时后,向每个孔中添加10μLCelltiter-Blue试剂,然后将细胞再孵育3小时。通过酶标仪(λex=560nm,λem=590nm)检测细胞活性,根据公式-6计算细胞存活率。
实验结果如图6所示。图6为水凝胶的生物安全性能——细胞存活率测试图,其中每一组柱形图中,从左往右依次为PBS组、PACP组、Nano-Ag组。
由图6可以看出,本申请提供的水凝胶细胞毒性较低,对生物体友好。
7、抗蛋白吸附性能测试:
通过耗散石英晶体微天平定量蛋白质在水凝胶上的吸附。将水凝胶附着在传感器表面,通过10%的FBS溶液到基线稳定,再用PBS溶液冲洗未结合蛋白到读数稳定。通过检测共振频率和耗散的变化,来计算吸附蛋白量。以聚(2-羟基乙基丙烯酸甲酯)(PHEMA)水凝胶作为阳性参照,分别设置交联度为0、1%、2%、5%、10%的胆碱磷酸水凝胶。各种水凝胶蛋白质吸附量见附图7。结果表明胆碱磷酸水凝胶具有优异的抗蛋白吸附能力,可显著防止蛋白沉积污垢,具有作为隐形眼镜、医用敷料、植入材料等医用材料的潜质。
8、抗菌性能测试:
根据GB/T 20944.3-2008标准中的振荡法测试时抑菌性能,大肠杆菌和金黄色葡萄球菌。过程简述如下:首先,将测试菌落置于10mL细菌营养液中,在37℃恒温振荡器中培养12h后,测试细菌浓度;然后,用PBS缓冲溶液稀释到108CFU/mL,取0.2g形状均一的凝胶样品加入到20mL目标浓度的菌液中,在37℃恒温振荡器中继续培养4h,然后取出适量菌液稀释并涂板培养,根据生长的菌落个数计算菌液浓度,利用公式-7计算抑菌率。以临床使用的一次性无菌敷贴、纳米银水胶敷贴作为对照,实验结果如表2所示:
表2水凝胶的抑菌性能结果汇总
(1)抑菌圈法:1cm×1cm溶胀状态贴片平铺在培养皿上,加入细菌悬浮液,在37℃培养24h,测试抑菌率。
(2)振荡法:1cm×1cm溶胀状态贴片平铺在培养皿上,加入细菌悬浮液,37℃、180rmp振荡12h,测试抑菌率。
(3)Y=(C1-C2)/C1×100%,C1菌液初始浓度,C2菌液最终浓度。
(4)细菌活死染色法。
由表2可以看出,本发明提供的水凝胶对大肠杆菌和金黄色葡萄球菌的抑菌率分别为:90.45%±1.34%和91.34%±1.58%(细菌初始浓度107CFU/mL),89.62%±2.42%和92.03%±3.01%(细菌初始浓度108CFU/mL),抑菌性能优异。
PACP高分子材料的抑菌性能测试如图8所示,在自然条件下,聚丙烯酸磷脂酰胆碱(PAPC)溶液少于45天开始因细菌滋生而发生霉变,而聚丙烯酸胆碱磷酸酯(PACP)则抑菌性能可以保持1年以上,而且可以制备透明度高的水凝胶,进一步说明胆碱磷酸功能材料具有优异的抑菌性能,可以广泛应用于生物医用领域以及工业塑料领域和民用塑料领域高端抗菌材料,具有重要的应用价值。
其中Wt是空白对照组菌液的浓度;
Qt是样品与菌液接触之后菌液的浓度。
以上实施例的说明只是用于帮助理解本发明的方法及其核心思想。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (10)
2.根据权利要求1所述的胆碱磷酸单体,其特征在于,所述R1、R2独立的选自取代或非取代的C1-C4的烷基;
所述R3选自取代或非取代的C1-C8的烷基、C3-C8的烯基、C3-C8的炔基、C3-C8的环氧基、C3-C8的叠氮基、C3-C8的氨基、多元醇类物质中除去任一羟基后剩余的残基、选择保护基团;
所述L1选自-C(=O)O-(CH2)n-、-C(=O)NH-(CH2)n-、-C(=O)O-(CH2CH2O)n-1-CH2CH2-或-C(=O)NH-(CH2CH2O)n-1-CH2CH2-,其中n是1-20的整数。
3.根据权利要求2所述的胆碱磷酸单体,其特征在于,所述R1、R2独立的选自甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基;
所述R3选自取代或非取代的甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、烯丙基、炔丙基、炔丁基;
所述L1选自-C(=O)O-(CH2)2-。
5.根据权利要求4所述的均聚物或共聚合物,其特征在于,所述R1、R2独立的选自取代或非取代的C1-C4的烷基;
所述R3选自取代或非取代的C1-C8的烷基、C3-C8的烯基、C3-C8的炔基、C3-C8的环氧基、C3-C8的叠氮基、C3-C8的氨基、多元醇类物质中除去任一羟基后剩余的残基、选择保护基团;
所述L1选自-C(=O)O-(CH2)n-、-C(=O)NH-(CH2)n-、-C(=O)O-(CH2CH2O)n-1-CH2CH2-或-C(=O)NH-(CH2CH2O)n-1-CH2CH2-,其中n是1-20的整数;
所述X1、X2独立的选自聚丙烯酸,聚丙烯腈,聚己酸内酯,聚乙交酯,聚乳酸,聚酰胺,聚氨酯,聚乙烯,氯化聚乙烯,聚氟乙烯,聚乙烯醇,聚甲醛,聚丙烯,氯化聚丙烯,聚苯乙烯,聚四氟乙烯,聚对苯二甲酸乙二(醇)酯,聚酰亚胺,聚甲基丙烯酰亚胺,聚甲基丙烯酸甲酯,聚硅氧烷,聚-2-(二异丙基氨基)丙烯酸乙酯,聚-3-羟基丁酸酯,聚二氧杂环己酮,聚三亚甲基碳酸酯,聚羧甲基纤维素,聚丙酸纤维素,乙交酯己内酯共聚物,丙烯腈-丁二烯-苯乙烯共聚物,丙烯腈-苯乙烯共聚物,丙烯腈-甲基丙烯酸酯共聚物,氯乙烯-甲基丙烯酸甲酯共聚物,乙烯-丙烯共聚物,全氟(乙烯-丙烯)共聚物,氯乙烯-丙烯酸甲酯共聚物,乙交酯三亚甲基碳酸脂共聚物和二氧杂环己酮-三亚甲基碳酸酯-乙交酯共聚物。
6.一种胆碱磷酸酯水凝胶,由胆碱磷酸单体,在交联剂存在的条件下,进行化学交联制备得到;
所述胆碱磷酸单体为权利要求1~3任一项所述的胆碱磷酸单体中的一种或多种,或权利要求4~5任一项所述的胆碱磷酸均聚物或共聚合物中的一种或多种。
7.根据权利要求6所述的胆碱磷酸酯水凝胶,其特征在于,所述交联剂选自N,N-亚甲基双丙烯酰胺。
8.根据权利要求6所述的胆碱磷酸酯水凝胶,其特征在于,所述化学交联的条件选自引发剂、紫外光照、加热、辐射中的一种或几种。
9.权利要求1~3任一项所述的胆碱磷酸单体,或权利要求4~5任一项所述的胆碱磷酸均聚物或共聚合物,或权利要求6~8任一项所述的胆碱磷酸酯水凝胶,作为生物医用材料的应用。
10.根据权利要求9所述的应用,其特征在于,所述生物医用材料包括治疗成分的载体、医疗器械、医用敷料、医用敷贴中的一种或多种;
所述治疗成分包括药物、基因、激素、疫苗中的一种或多种;
所述医疗器械包括稀释剂、抗生物污染、抑菌、植入器械表面抗污涂层;
所述医用敷料包括水胶体抗菌敷料、水胶体清洁抗菌促愈合敷料中的一种或多种;
所述医用敷贴包括医用一次性抗菌敷贴,粘贴型抗菌敷贴,透明抗菌敷贴,伤口胶体敷贴。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110614144.6A CN113336795A (zh) | 2021-06-02 | 2021-06-02 | 胆碱磷酸单体及其聚合物以及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110614144.6A CN113336795A (zh) | 2021-06-02 | 2021-06-02 | 胆碱磷酸单体及其聚合物以及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113336795A true CN113336795A (zh) | 2021-09-03 |
Family
ID=77473070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110614144.6A Pending CN113336795A (zh) | 2021-06-02 | 2021-06-02 | 胆碱磷酸单体及其聚合物以及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113336795A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11166015A (ja) * | 1991-07-05 | 1999-06-22 | Biocompatibles Ltd | 表面を生物および血液適合性にするために有用なポリマー |
CN101962422A (zh) * | 2010-08-06 | 2011-02-02 | 浙江大学 | 具有内皮细胞选择性的心血管支架涂层材料及其制备和应用方法 |
KR20130071517A (ko) * | 2011-12-21 | 2013-07-01 | 주식회사 케이씨아이 | 초임계 유체를 이용한 무용제형 아크릴산 단량체와 포스포릴콜린 유사기 함유 단량체 기반의 가교 결합 공중합체의 제조방법 및 이를 포함하는 화장료 조성물 |
CN103917548A (zh) * | 2011-06-24 | 2014-07-09 | 生物相互作用有限公司 | 生物相容的仿生两性电解质材料 |
CN110540551A (zh) * | 2019-09-09 | 2019-12-06 | 中国科学院长春应用化学研究所 | 一种脂质体、其制备方法、脂质体组装体及载物脂质体复合体 |
CN112384284A (zh) * | 2018-03-23 | 2021-02-19 | 华盛顿大学 | 免疫抑制性材料及相关方法 |
AU2019399661A1 (en) * | 2018-12-10 | 2021-05-20 | Seed Co., Ltd. | UV absorbing ocular lens |
-
2021
- 2021-06-02 CN CN202110614144.6A patent/CN113336795A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11166015A (ja) * | 1991-07-05 | 1999-06-22 | Biocompatibles Ltd | 表面を生物および血液適合性にするために有用なポリマー |
CN101962422A (zh) * | 2010-08-06 | 2011-02-02 | 浙江大学 | 具有内皮细胞选择性的心血管支架涂层材料及其制备和应用方法 |
CN103917548A (zh) * | 2011-06-24 | 2014-07-09 | 生物相互作用有限公司 | 生物相容的仿生两性电解质材料 |
KR20130071517A (ko) * | 2011-12-21 | 2013-07-01 | 주식회사 케이씨아이 | 초임계 유체를 이용한 무용제형 아크릴산 단량체와 포스포릴콜린 유사기 함유 단량체 기반의 가교 결합 공중합체의 제조방법 및 이를 포함하는 화장료 조성물 |
CN112384284A (zh) * | 2018-03-23 | 2021-02-19 | 华盛顿大学 | 免疫抑制性材料及相关方法 |
AU2019399661A1 (en) * | 2018-12-10 | 2021-05-20 | Seed Co., Ltd. | UV absorbing ocular lens |
CN110540551A (zh) * | 2019-09-09 | 2019-12-06 | 中国科学院长春应用化学研究所 | 一种脂质体、其制备方法、脂质体组装体及载物脂质体复合体 |
Non-Patent Citations (4)
Title |
---|
GAOJIE HU,等: "A facile approach to hydrophilic, reverse zwitterionic, choline phosphate polymers", 《POLYM. CHEM.》 * |
GAOJIE HU,等: "Functional Choline Phosphate Polymers", 《J. AM. CHEM. SOC.》 * |
WEN-LIANG WANG,等: "pH-responsive Polymersome Based on PMCP-b-PDPA as a Drug Delivery System to Enhance Cellular Internalization and Intracellular Drug Release", 《CHINESE JOURNAL OF POLYMER SCIENCE》 * |
王文靓: "磷杂环戊烷开环材料在纳米药物载体及生物医用凝胶中的应用研究", 《中国博士学位论文全文数据库 工程科技Ⅰ辑》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020139163A (ja) | 官能性双性イオン性ポリマーおよび混合電荷ポリマー、関連するヒドロゲルならびにこれらの使用方法 | |
CN106046382B (zh) | 一种装载一氧化氮的阳离子聚合物及其制备方法和应用 | |
Feksa et al. | Hydrogels for biomedical applications | |
JP5783988B2 (ja) | 高分子電解質を含む親水性コーティング | |
JP5499321B2 (ja) | 医療コーティングのためのコーティング調合物 | |
Polat et al. | Agar/κ-carrageenan/montmorillonite nanocomposite hydrogels for wound dressing applications | |
Benamer et al. | Synthesis and characterisation of hydrogels based on poly (vinyl pyrrolidone) | |
JP5521237B2 (ja) | 親水性コーティング | |
Yuan et al. | Immobilization of gelatin onto poly (glycidyl methacrylate)-grafted polycaprolactone substrates for improved cell–material interactions | |
SG177516A1 (en) | Chitosan hydrogel derivatives as a coating agent with broad spectrum of antimicrobial activities | |
ES2350403T3 (es) | Revestimiento hidrófilo que comprende un polielectrólito. | |
Conzatti et al. | Surface functionalization of plasticized chitosan films through PNIPAM grafting via UV and plasma graft polymerization | |
CN107474160A (zh) | 一种磷酰胆碱基聚乙二醇改性壳聚糖及其制备方法 | |
CN107033372A (zh) | 具有多重响应功能的水凝胶及其制备方法和用途 | |
CN112226136A (zh) | 一种纳米复合材料防雾抗菌涂层的制备方法 | |
Woo et al. | Functional ferrocene polymer multilayer coatings for implantable medical devices: Biocompatible, antifouling, and ROS-sensitive controlled release of therapeutic drugs | |
JP6195335B2 (ja) | 高分子化合物、及びそれを用いた組成物、医療機器 | |
CN110028614A (zh) | 具有蛋白吸附功能的抗菌微纳米凝胶与纤维及其制备方法 | |
CN113336795A (zh) | 胆碱磷酸单体及其聚合物以及应用 | |
CN105504328A (zh) | 一种室温下一步涂覆改善壳聚糖膜血液相容性的方法 | |
JP3580022B2 (ja) | ブロック共重合体および医療用材料 | |
Hamid et al. | Synthesis of Acrylamide-Graphene Oxide Polymer for Antibacterial Application | |
Bilal et al. | Valorization of Green and Sustainable Advanced Materials from A Biomed Perspective–Potential Applications | |
Shirazi et al. | pH-thermoresponsive hydrogel-treated fabric for treating reinfected wounds | |
CN115403502B (zh) | 一种离子液体-近红外荧光探针水凝胶及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210903 |